AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 3rd, 2016 • Cytokinetics Inc • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LETTER OF AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND AMGEN INC. AND LES LABORATOIRES SERVIER AND INSTITUT DE RECHERCHES INTERNATIONALES SERVIER DATED AUGUST 29, 2016Letter of Agreement • November 3rd, 2016 • Cytokinetics Inc • Pharmaceutical preparations
This Letter of Agreement (this “Agreement”) is entered into as of August 29, 2016 (the “Effective Date”) by and between Cytokinetics, Incorporated, a Delaware corporation having its principal place of business at 280 East Grand Avenue, South San Francisco, California 94080, U.S.A. (“Cytokinetics”), and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Les Laboratoires Servier, a French corporation having its principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a French corporation having its principal place of business at 50 rue Carnot, 92150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”). Cytokinetics, Amgen and Servier are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
